Advertisement

Topics

Latest Prostate Cancer research and development NewsRSS

06:48 EDT 29th June 2017 | BioPortfolio

Dr. Marvell Scott: Sports Can Enhance Heart Function

NEW YORK, June 19, 2012 /PRNewswire/ -- According to a MSN story, a new study has found that breast cancer survivors can improve their heart's health and reduce the chances of a relapse by participating in competitive sports. Dr. Marvell Scott, creator of the Performance Health Program, said it is imperative patients consider heart rate-based training to get the most of their training program. Thi...

Cervical CancerMarket Insights, Epidemiology and Market Forecast2023 United States [Report Updated: 30052017] Prices from USD $2083

DelveInsight's Cervical Cancer Market Insights, Epidemiology and Market Forecast2023 United States Report provides marketed drugs information of Cervical Cancer. It includes historical and forecasted epidemiology and market size of the Cervical Cancer of US for 20132023.DelveInsight estimates that the market size of Cervical Cancer in United States is expected to grow at a Compound Annual Growth R...

Henry Arms Makes Major Donation To The Roger Maris Cancer Center

FARGO, N.D., June 24, 2012 /PRNewswire/ -- Anthony Imperato, President of Henry Repeating Arms of Brooklyn, N.Y., presented a $61,000 donation to the Roger Maris Cancer Center at the 2012 Roger Maris Celebrity Golf Tournament banquet on Sunday night. (Photo: http://photos.prnewswire.com/prnh/20120624/NY29644 ) "Because of the proximity to Yankee Stadium many of the Henry Repeating Arms staff are...

Advanced Radiotherapy Techniques Explored at Educational Events in India

AHMEDABAD, India, June 26, 2012 /PRNewswire/ -- HCG Cancer Centre, the first hospital in India to introduce clinical treatments using an advanced TrueBeam™ treatment system from Varian Medical Systems (NYSE: VAR), has conducted a workshop focusing on stereotactic body radiotherapy (SBRT) for treating cancers of the lung, liver, spine, and prostate.  More than 150 specialists from across...

Minomic Clinical Study Progresses For MiltuximabTM In Prostate, Bladder, and Pancreatic Cancer

Drug Safety Monitoring Committee Approval to Proceed to Final Six Patients of Twelve First-in-human trial on safety and tolerability passes key stage-gate Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-3...

Endometrial Cancer Epidemiology Forecast To 2023 [Report Updated: 31052017] Prices from USD $2338

DelveInsight Endometrial Cancer Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Endometrial Cancer in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Endometrial Cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevaili...

Pamela W. Coleman, M.D., F.A.C.S., F.P.M.R.S., is recognized by Continental Who's Who

WASHINGTON, June 28, 2017 /PRNewswire/ -- Pamela W. Coleman, M.D., F.A.C.S., F.P.M.R.S., is recognized by Continental Who's Who as a Pinnacle Professional of the Year in the medical field. Dr. Coleman is Interim Chief of and an Associate Professor of Urology at Howard University Hospital (HUH) in Washington, D.C. She earned her Bachelors of Science in chemistry, with a minor in math, from Geor...

Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR® Hydrogel in Israel

The Chaim Sheba Medical Center now offers the hydrogel spacer to reduce side-effects during prostate cancer radiation therapy Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, today announced that the first patients have been...

Lung Cancer Video Library – First Line Combinations, Immunotherapy with Chemo

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses First Line Combinations, Immunotherapy with Chemotherapy.Related Posts:Why Give Adjuvant Chemotherapy

Colorectal CancerGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30052017] Prices from USD $1700

DelveInsight's Report, Colorectal CancerGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Colorectal Cancer Report is to understand the market and pipeline status of the drugs around the Colorectal Cancer to explor...

City of Hope Named “Leader in LGBTQ Healthcare Equality” by Human Rights Campaign Foundation

The elite nationwide designation reflects a perfect score, outstanding LGBTQ patient-centered care City of Hope, a world-renowned independent research and cancer and diabetes treatment center, today announced it has received the “Leader in LGBTQ Healthcare Equality” designation from the Human Rights Campaign Foundation (HRC), the educational...

Professor Tayyaba Hasan Receives IPA Award for Significant Advancement of Photodynamic Therapy

COIMBRA, Portugal, June 28, 2017 /PRNewswire/ -- At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Professor Tayyaba Hasan was the recipient of the 2017 AWARD FOR SIGNIFICANT ADVANCEMENT OF PHOTODYNAMIC THERAPY. Dr. Tayyaba Hasan is a Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health S...

Pioneering Allegheny Health Network Cancer Specialist Norman Wolmark, MD, Receives Distinguished “Giants of Cancer Care” Recognition

Dr. Norman Wolmark, Allegheny Health Network breast surgeon, is among 12 respected healthcare professionals nationwide honored as "Giants of Cancer Care" for their contributions to research and clinical practice. PITTSBURGH, Pa (PRWEB) June 28, 2017 Norman Wolmark, MD, an internationally recognized cancer surgeon and Medical Director of Breast Surgical Oncology, Cancer Research and Clin...

Proto Oncogene Tyrosine Protein Kinase ROS Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1 Pipeline Review, H1 2017 [Report Updated: 27062017] Prices from USD $3500

Proto Oncogene Tyrosine Protein Kinase ROS Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1 Pipeline Review, H1 2017SummaryProto Oncogene Tyrosine Protein Kinase ROS Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1 Protooncogene tyrosineprotein k...

Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR Pipeline Review, H1 2017 [Report Updated: 27062017] Prices from USD $3500

Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR Pipeline Review, H1 2017SummaryAccording to the recently published report 'Aryl Hydrocarbon Receptor Pipeline Review, H1 2017'; Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are devel...

Bromodomain Testis Specific Protein Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT Pipeline Review, H1 2017 [Report Updated: 27062017] Prices from USD $3500

Bromodomain Testis Specific Protein Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT Pipeline Review, H1 2017SummaryBromodomain Testis Specific Protein Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT Bromodomain testisspecific protein is a protein encoded by the BRDT gene. It plays a role in meiotic and postmeiotic cells by binding to acetylated histones at the promoter of specific me...

Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 Pipeline Review, H1 2017 [Report Updated: 27062017] Prices from USD $3500

Macrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 Pipeline Review, H1 2017SummaryMacrophage Colony Stimulating Factor 1 Receptor CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1 pipeline Target constitutes close to 33 molecules. Out of which approximately 32 molecules are developed by companies and remain...

Hitting Cancer from All Sides

SANTA ROSA, Calif., Aug. 20, 2012 /PRNewswire/ -- Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can co...

Radiotherapy Market Growing at a CAGR of 6.8% During 2017 to 2022 - ReportsnReports.com

PUNE, India, June 28, 2017 /PRNewswire/ -- Radiotherapy market is expected to reach $9.47 billion by 2022 from $6.81 billion in 2017, at a CAGR of 6.8%. Prostate cancer holds the largest share by application while Cancer research institutes will grow at the highest CAGR with APAC region to witness the highest growth Browse 116 tables and 36 figures, 25 Company profiles spread across 222 pa...

Optical Technology Detects Cancer With High Accuracy During Surgery

An intraoperative, multimodal optical cancer detection system can detect brain cancer with high degrees of accuracy, sensitivity, and specificity in real time during surgery, according to a new study.

Blind faith: Do we place too much confidence in cancer tests?

Cervical CancerMarket Insights, Epidemiology and Market Forecast2023 [Report Updated: 30052017] Prices from USD $4208

DelveInsight's Cervical Cancer Market Insights, Epidemiology and Market Forecast2023Global Report provides an overview of the disease and global market size of the Cervical Cancer for the 7MM United States, EU5 France, Germany, Italy, Spain and UK and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Cervical Cancer from 20132023. Del...

Serine/Threonine Protein Kinase ATR Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1 Pipeline Review, H1 2017 [Report Updated: 20062017] Prices from USD $3500

Serine/Threonine Protein Kinase ATR Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1 Pipeline Review, H1 2017SummaryAccording to the recently published report 'SerineThreonine Protein Kinase ATR Pipeline Review, H1 2017'; Serine/Threonine Protein Kinase ATR Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1...

Lumicell Appoints Felix Geissler, M.D., Ph.D. as Chief Medical Officer

Lumicell, a leader in the field of image-guided cancer surgery, today announced the appointment of Felix Geissler, M.D., Ph.D. as Chief Medical Officer. As a central member of Lumicell’s senior executive team, he will drive the clinical direction of the company and will work closely with the R&D and marketing teams to develop the overall business str...

Cancer-Focused Vivace Emerges with $40M in Financing

A cancer-focused drug discoverer and developer emerged from stealth mode by disclosing today that it has raised $40 million in Series A and Series B financings. Vivace Therapeutics said that its $25 million Series B financing was led by new investor Cenova Capital and included another new investor, Sequoia Capital China, as well as existing investors Canaan Partners, WuXi Healthcare Ventures a...

Quick Search
Advertisement
 

review and buy Prostate Cancer research and development market research data and corporate reports here